Fregonese F, et al. - This meta-analysis was conducted to draw a comparison in the success, mortality, and acquired rifampicin resistance in patients with isoniazid-resistant, rifampicin-susceptible (INH-R) pulmonary tuberculosis given different durations of rifampicin, ethambutol, and pyrazinamide (REZ); a fluoroquinolone plus 6 months or more of REZ; and streptomycin plus a core regimen of REZ. Compared with treatment with at least 6 months of daily REZ, in patients with INH-R tuberculosis, the addition of a fluoroquinolone was related to better treatment success, whereas less treatment success was seen with the addition of streptomycin.